Northcape Wealth Management LLC Invests $2.75 Million in Stryker Corporation $SYK

Northcape Wealth Management LLC bought a new stake in Stryker Corporation (NYSE:SYK - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 8,724 shares of the medical technology company's stock, valued at approximately $2,747,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sankala Group LLC acquired a new position in Stryker in the fourth quarter valued at $26,000. Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker during the fourth quarter worth about $26,000. United Financial Planning Group LLC purchased a new stake in shares of Stryker in the 3rd quarter valued at about $27,000. Atlas Capital Advisors Inc. acquired a new stake in shares of Stryker in the 4th quarter valued at about $27,000. Finally, Gables Capital Management Inc. purchased a new position in Stryker during the 2nd quarter worth approximately $25,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Up 2.7%

SYK stock opened at $340.20 on Thursday. The stock has a market capitalization of $130.49 billion, a PE ratio of 35.25, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. The company has a fifty day moving average of $326.19 and a 200-day moving average of $332.95. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analysts' expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm's revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the prior year, the company posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker's dividend payout ratio (DPR) is currently 36.48%.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of research reports. Wolfe Research lowered shares of Stryker from an "outperform" rating to a "peer perform" rating in a research report on Thursday, August 13th. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on shares of Stryker in a research report on Friday, May 1st. Wall Street Zen upgraded shares of Stryker from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Robert W. Baird set a $385.00 target price on shares of Stryker in a report on Friday, May 1st. Finally, UBS Group initiated coverage on shares of Stryker in a research note on Tuesday, July 28th. They set a "buy" rating and a $400.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $386.28.

Insider Activity

In related news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company's stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 315,370 shares of company stock valued at $98,463,501 in the last three months. 4.60% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source